Mutlu Hizal1, Mehmet An Sendur1, Hatime Arzu Yasar2,3, Kadriye Bir Yucel4, Cagatay Arslan5, Gokhan Ucar6, Serdar Karakaya7, Hakan Taban8, Ahmet Kucukarda9, Ismail Erturk10, Burak Bilgin1, Nuriye Yıldırım11, Umut Demirci7, Saadettin Kılıckap8, Irfan Cicin9, Nuri Karadurmus10, Bulent Yalcin1, Yüksel Ürün2,3. 1. Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey. 2. Medical Oncology Department, Ankara University School of Medicine, Ankara, Turkey. 3. Ankara University Cancer Research Institute, Ankara, Turkey. 4. Internal Medicine Department, Ankara University Faculty of Medicine, Ankara, Turkey. 5. Department of Internal Medicine and Medical Oncology, Bahcesehir University Faculty of Medicine, Istanbul, Turkey. 6. Medical Oncology Department, University of Health Sciences, Ankara Numune Education and Research Hospital, Ankara, Turkey. 7. Medical Oncology Department, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey. 8. Medical Oncology Department, Hacettepe University Faculty of Medicine, Ankara, Turkey. 9. Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey. 10. Medical Oncology Department, University of Health Sciences, Gülhane Education and Research Hospital, Ankara, Turkey. 11. Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
Abstract
BACKGROUND: To describe the prognostic value of neutrophil-lymphocyte ratio and its effect on survival in in patients with advanced renal cell carcinoma. METHODS: We retrospectively analyzed 331 patients. The cut-off value of neutrophil-lymphocyte ratio was specified as "3" which is mostly close-and also clinically easily applicable-to the median neutrophil-lymphocyte ratio level of our study group. High group is identified as neutrophil-lymphocyte ratio >3 (n = 160) and low group is identified as neutrophil-lymphocyte ratio ≤3 (n = 163). RESULTS: A total of 331 (with 211 male and 120 female) patients were enrolled to study. The median age of the patients was 58. The International Metastatic RCC Database Consortium risk score is calculated for the 72.8% (n = 241) of the study group and among these patients, favorable, intermediate, and poor risk rates were 22, 45.2, and 32.8%. The total usage of tyrosine kinase inhibitors reached 78% of the patients. The median overall survival was 32 months versus 11 months in the neutrophil-lymphocyte ratio low and high groups, respectively (HR: 0.49 (95% CI 0.37-0.65), p < 0.001). CONCLUSION: In conclusion, the pre-treatment value of elevated neutrophil-lymphocyte ratio might be a predictor of poor overall survival in advanced renal cell carcinoma patients.
BACKGROUND: To describe the prognostic value of neutrophil-lymphocyte ratio and its effect on survival in in patients with advanced renal cell carcinoma. METHODS: We retrospectively analyzed 331 patients. The cut-off value of neutrophil-lymphocyte ratio was specified as "3" which is mostly close-and also clinically easily applicable-to the median neutrophil-lymphocyte ratio level of our study group. High group is identified as neutrophil-lymphocyte ratio >3 (n = 160) and low group is identified as neutrophil-lymphocyte ratio ≤3 (n = 163). RESULTS: A total of 331 (with 211 male and 120 female) patients were enrolled to study. The median age of the patients was 58. The International Metastatic RCC Database Consortium risk score is calculated for the 72.8% (n = 241) of the study group and among these patients, favorable, intermediate, and poor risk rates were 22, 45.2, and 32.8%. The total usage of tyrosine kinase inhibitors reached 78% of the patients. The median overall survival was 32 months versus 11 months in the neutrophil-lymphocyte ratio low and high groups, respectively (HR: 0.49 (95% CI 0.37-0.65), p < 0.001). CONCLUSION: In conclusion, the pre-treatment value of elevated neutrophil-lymphocyte ratio might be a predictor of poor overall survival in advanced renal cell carcinomapatients.